| 65232 | |
| Alzheimer's disease is a progressive mental deterioration, resulting in loss of memory, confusion and disorientation, and other behavioral problems. Unfortunately, no definitive cure has been developed to treat this disease. Beta-secretase, an important enzyme in the development and onset of Alzheimer's disease, contributes to the formation of amyloid-beta peptides that aggregate in the brain of Alzheimer's patients. Blocking beta-secretase is a potential strategy for the treatment of Alzheimer's disease. Researchers at Purdue University have developed a series of novel compounds for beta-secretase inhibition that offer improved pharmacological properties. Novel peptidomimetic scaffolds were utilized to replace conventional hydroxyethylamine isosteres and were shown to be good inhibitors of beta-secretase. This series of compounds shows increased potency, improved aqueous solubility, increased metabolic stability, and improved oral bioavailability over previously identified inhibitors or beta-secretase. Advantages: -Improved pharmacological properties -Shown to be good inhibitors of beta-secretase Potential Applications: -Medical/Health -Pharmaceutical Industry |
|
|
|
|
Jun 3, 2011
Utility Patent
United States
8,859,590
Oct 14, 2014
Nov 16, 2010
Provisional-Patent
United States
(None)
(None)
Dec 4, 2009
PCT-Patent
WO
(None)
(None)
May 27, 2009
Provisional-Patent
United States
(None)
(None)
Dec 5, 2008
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |